Prognostic impact of germinal center B-cell-like and non-germinal center B-cell-like subtypes of bone marrow involvement in patients with diffuse large B-cell lymphoma treated with R-CHOP

The prognostic significances of the germinal center B-cell-like (GCB) and non-germinal center B-cell-like (non-GCB) types of diffuse large B-cell lymphoma (DLBCL) have been reported to be different. We analyzed the effect of the cell of origin (COO) of bone marrow (BM) involvement in patients with D...

Full description

Saved in:
Bibliographic Details
Published in:Medicine (Baltimore) 2018-11, Vol.97 (45), p.e13046-e13046
Main Authors: Cho, Min-Chul, Chung, Yousun, Jang, Seongsoo, Park, Chan-Jeoung, Chi, Hyun-Sook, Huh, Jooryung, Suh, Cheolwon, Shim, Hyoeun
Format: Article
Language:English
Subjects:
Adolescent
Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal, Murine-Derived - administration & dosage
Antineoplastic Combined Chemotherapy Protocols - administration & dosage
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
B-Lymphocytes - pathology
Bone Marrow - pathology
Cyclophosphamide - administration & dosage
Disease-Free Survival
Doxorubicin - administration & dosage
Female
Germinal Center - pathology
Humans
Kaplan-Meier Estimate
Lymphoma, Large B-Cell, Diffuse - drug therapy
Lymphoma, Large B-Cell, Diffuse - pathology
Male
Middle Aged
Observational Study
Prednisone - administration & dosage
Prognosis
Rituximab
Treatment Outcome
Vincristine - administration & dosage
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The prognostic significances of the germinal center B-cell-like (GCB) and non-germinal center B-cell-like (non-GCB) types of diffuse large B-cell lymphoma (DLBCL) have been reported to be different. We analyzed the effect of the cell of origin (COO) of bone marrow (BM) involvement in patients with DLBCL who were treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in a single institute.The subtype of BM involvement was evaluated in 633 patients who were diagnosed with primary DLBCL and had been treated with R-CHOP. BM trephine biopsies were analyzed, and immunohistochemical staining of CD20, CD79a, and CD3 was performed. Additional staining of CD10, Bcl-6, and MUM1 was performed to determine the COO based on a previously reported algorithm.BM involvement was present in 81 patients (12.8%). Among them, 30 patients (37.0%) had GCB-type BM involvement and 51 (63.0%) showed non-GCB-type involvement. Kaplan-Meier survival analysis showed that the non-GCB type had the worst progression-free survival (PFS) and overall survival (OS) (P 
ISSN:0025-7974
1536-5964
DOI:10.1097/MD.0000000000013046